NSABP FC-10
Select A Category

NSABP FC-10

A Phase IB Study of Pembrolizumab in Combination with Pemetrexed and Oxaliplatin in Patients with Chemo-refractory Metastatic Colorectal Cancer

Protocol Chair: James J. Lee, MD, PhD

Protocol Officer: Thomas George, MD

Primary Objective: 1) to establish the recommended Phase II dose (RP2D) of pembrolizumab in combination with pemetrexed and oxaliplatin and 2) evaluate the antitumor efficacy.

Patient Population: Metastatic Colorectal Cancer

Target Accrual: 33 patients

Status: Recruiting patients

ClinicalTrials.gov Identifier:NCT03626922